Compounds > 2-phenylamino-4-methyl-5-acetylthiazole
Page last updated: 2024-11-09

2-phenylamino-4-methyl-5-acetylthiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-phenylamino-4-methyl-5-acetylthiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID735838
CHEMBL ID1235108
SCHEMBL ID17324735
MeSH IDM0535741

Synonyms (38)

Synonym
AKOS001114487
UPCMLD0ENAT5384045:001
EU-0011442
2-phenylamino-4-methyl-5-acetyl thiazole
p4t ,
2VBA
1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethanone
STK397562
DB08359
1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethanone
chembl1235108 ,
bdbm50071795
MLS003315829
smr001994964
5-acetyl-4-methyl-2-(phenylamino)thiazole
5-acetyl-4-methyl-2-(phenylamino)-1,3-thiazole
4-[(2s)-2-hydroxy-3-[(1-methylethyl-d7)amino]propoxy]benzeneacetamide
1-[4-methyl-2-(phenylamino)-1,3-thiazol-5-yl]ethan-1-one
MS-6525
31609-42-4
HMS3604J17
SR-01000492496-1
sr-01000492496
SCHEMBL17324735
2-phenylamino-4-methyl-5-acetylthiazole, aldrichcpr
mfcd00129318
2-phenylamino-4-methyl-5-acetylthiazole
DTXSID60352855
1-(2-anilino-4-methyl-1,3-thiazol-5-yl)ethan-1-one
1-(2-anilino-4-methyl-1,3-thiazol-5-yl)-1-ethanone
1-(4-methyl-2-phenylaminothiazol-5-yl)ethanone
1-(4-methyl-2-(phenylamino)thiazol-5-yl)ethanone
Q27097573
A936171
1-(4-methyl-2-(phenylamino)thiazol-5-yl)ethan-1-one
CS-0313581
EN300-7408259
PD004472
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nrf2Homo sapiens (human)Potency14.12340.09208.222223.1093AID624171; AID651593; AID651597
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)IC50 (µMol)10.00000.00050.742710.0000AID1196770
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)10.00000.23002.64439.4800AID1196771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
Chain A, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
Chain B, 3-OXOACYL-[ACYL-CARRIER-PROTEIN] SYNTHASE 1Escherichia coliKd25.000025.000025.000025.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
UDP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' UMP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
pyrimidine ribonucleotide biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
dihydroorotase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
protein bindingDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase (quinone) activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrionDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
cytosolDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1196770Inhibition of human DHODH using dihydroorotate substrate by DCIP assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.
AID1196781Retention time of the compound2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.
AID660183Inhibition of IL-1beta-induced PGE2 production in human HCA-7 cells after 72 hrs by EIA2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
AID660180Inhibition of IL-1beta-induced PGE2 production in human HCA-7 cells at 1 uM after 72 hrs by EIA2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
AID1196771Inhibition of Plasmodium falciparum DHODH using dihydroorotate substrate by DCIP assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.
AID660181Inhibition of COX2 at 5 uM by fluorescence assay2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
AID660182Inhibition of COX2 by fluorescence assay2012Bioorganic & medicinal chemistry letters, May-15, Volume: 22, Issue:10
Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2007Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 63, Issue:Pt 12
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.
AID1811Experimentally measured binding affinity data derived from PDB2007Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 63, Issue:Pt 12
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		2.0710organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
thiazoles
[no description available]		2.03101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
methotrexate
[no description available]		2.1110dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
teriflunomide
[no description available]		2.1110(trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide		drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor
thiolactomycin
thiolactomycin: from actinomycetes; structure given in first source		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510